Esófago de Barrett. Neoplasias esofágicas

  1. Monteserín Ron, L. 1
  2. Domínguez Muñoz, J.E. 1
  1. 1 Servicio Aparato Digestivo, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, La Coruña, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2020

Título do exemplar: Enfermedades del aparato digestivo (VII)Enfermedades del esófago

Serie: 13

Número: 7

Páxinas: 392-400

Tipo: Artigo

DOI: 10.1016/J.MED.2020.05.004 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumo

Barrett's oesophagus is the main complication of gastro-oesophageal reflux disease. The disease is an acquired condition in which there is the replacement of the distal oesophageal squamous epithelium present in normal conditions by a cylindrical epithelium with the presence of intestinal metaplasia. The importance of this disease lies in its potential to degenerate into oesophageal adenocarcinoma. These patients should therefore undergo endoscopic follow-up for the early detection of dysplasia or adenocarcinoma. Adenocarcinoma and squamous cell carcinoma are the 2 most common malignant oesophageal neoplasms, both of which are associated with smoking. Oesophageal cancer is the seventh most common tumour worldwide and has a high mortality rate, given that it usually progresses asymptomatically in the initial phases. Proper staging will indicate the most appropriate treatment in each case.

Referencias bibliográficas

  • Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, Casanova S, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: Loiano-Monghidoro study. Gut. 2008;57:1354-59.
  • Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825-31.
  • Juhasz A, Mittal SK, Lee TH, Deng C, Chak A, Lynch HT. Prevalence of Barrett’s Esophagus in first degree relatives of patients with esophageal adenocarcinoma. J Clin Gastroenterol. 2011;45:867-71.
  • Savarino E, De Bortoli N, De Cassan C, Della Coletta M, Bartolo O, Furnari M, et al. The natural history of gastro-esophageal reflux disease: a comprehensive review. Dis Esophagus. 2017;30:1-9.
  • Menges M, Muller M, Zeiz M. Increased acid and bile reflux in Barrett’s esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol. 2001;96:331-7.
  • Singh P, Taylor RH, Coli-Jones DG. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett’s metaplasia is present. Am J Gastroenterol. 1994;89:349-56.
  • Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol. 2016;111:30-50.
  • Anderson LA, Cantwell MM, Watson RG, Johnston BT, Murphy SJ, Fer-guson HR, et al. The association between alcohol and reflux esophagitis, Barrett’s esophagus, and esophageal adenocarcinoma. Gastroenterology. 2009;136:799-805.
  • Weusten B, Bisschops R, Coron E, Dinis-Ribeiro M, Dumon-ceau JM, Esteban JM, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017;49:191-8.
  • Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7-42.
  • ASGE Standards of Practice Committee, Evans JA, Early DS, Fukami N, Ben-Menachem T, Chandrasekhara V, et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012;76:1087-94.
  • Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375-83.
  • Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: A meta-analysis. Gut. 2012;61(7):970-6.
  • Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008; 67(3): 394-8.
  • Haidry RJ, Magee C. Mistakes in the endoscopic diagnosis and management of Barrett’s oesophagus and how to avoid them. UEG Education 2018; 2018:12-14.
  • Gupta N, Gaddam S, Wani SB, Bansal A, Rastogi A, Sharma P. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc. 2012;76(3):531-8.
  • Visrodia K, Singh S, Krishnamoorthi R, Ahlquist DA, Wang KK, Iyer PG, et al. Magnitude of missed esophageal adenocarcinoma after Barrett’s esophagus diagnosis: a systematic review and meta-analysis. Gastroente-rology. 2016;150:599-607.e7.
  • Abrams JA, Kapel RC, Lindberg GM, Saboorian MH, Genta RM, Neu-gut AI, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol. 2009;7:736-42.
  • Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: The Prague C&M Criteria. Gastroenterology. 2006; 131(5):1392-9.
  • Sharma P, Hawes RH, Bansal A, Gupta N, Curvers W, Rastogi A, et al. Standard endoscopy with random biopsies vs NBI targeted biopsies in Barrett’s oesophagus: a prospective, international, randomised controlled trial. Gut. 2013;62:15-21.
  • Duits LC, Phoa KN, Curvers WL, Ten Kate FJ, Meijer GA, Seldenrijk CA, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64:700-6.
  • De la Coba C, Argüelles-Arias F, Martín-de-Argila C, Júdez J, Linares A, Ortega-Alonso A, et al. Efectos adversos de los inhibidores de la bomba de protones: revisión de evidencias y posiciona-miento de la Sociedad Española de Patología Digestiva. Rev Esp Enferm Dig. 2016;108:207-24.
  • Iyer PG, Kaul V. Barrett esophagus. Mayo Clin Proc. 2019;94(9):1888-901.
  • Standards of Practice Committee, Wani S, Qumseya B, Sultan S, Agrawal D, Chandrasekhara V, Harnke B, et al. Endoscopic eradication therapy for patients with Barrett’s esophagus-associated dysplasia and intramucosal cancer. Gastrointest Endosc. 2018;87(4):907-31.e9.
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394-424.
  • Thrift AP. The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol. 2016;41:88.
  • Peter C, Enzinger MD, Robert J, Mayer MD. Esophageal cancer review article. N Engl J Med. 2003;349:2241-52.
  • Domper MJ, Ferrández A, Lanas A. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21(26):7933-43.
  • Wheeler JB, Reed CE. Epidemiology of esophageal cancer. Surg Clin North Am. 2012;92:1077-87.
  • Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119-30.
  • Martin-Richard M, Díaz Beveridge R, Arrazubi V, Alsina M, Galan Guz-mán M, Custodio AB, et al. SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016). Clin Transl Oncol. 2016; 18(12):1179-86.
  • ASGE Standards of Practice Committee, Evans JA, Early DS, Chandras-khara V, Chathadi KV, Fanelli RD, Fisher DA, et al. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc. 2013;77(3):328-34.
  • Spaander MC, Baron TH, Siersema PD, Fuccio L, Schumacher B, Escor-sell À, et al. Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2016;48(10):939-48.
Fonte de datos: Dialnet